We aim to be a leading global innovator in the biotechnology industry by continuously developing ground-breaking molecular diagnostic (MDx) technologies, increasing health awareness in society and inspiring future generations in order to achieve a healthier community with higher standard of living.

We are to be concerned with their health by striving ourselves toward “A step ahead for healthcare”.

Molecular diagnostics technology moves fast. Newer tests tend to be quicker, more revealing and more expensive. Older tests often cost less but may not be as informative. There is a valuable role for both. Our goal is to give medical professionals and patients the widest possible choice. Our technology includes cutting edge next-generation sequencing (NGS) and other frequently used methods such as RT-PCR and Sanger sequencing.

NGS technology targets genes and mutations relevant to particular cancers. With significantly higher read length and read depth than traditional techniques, NGS allows us to sequence large genomic regions, providing comprehensive genetic profiles in a single efficient and cost-effective report. This form of testing helps identify rare somatic mutations which may have been misinterpreted as negative.